NASDAQ$NUVL
Nuvalent Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Nuvalent reported Q3 2023 financial results and highlighted corporate and pipeline achievements.
Nuvalent reported a net loss of $33.6 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $413.3 million as of September 30, 2023, which, combined with the proceeds from a recent public offering, are expected to extend the operating runway into 2027.
- Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655.
- Initiated Phase 2 portion of ARROS-1 trial of NVL-520.
- Continued advancement of NVL-330 toward clinical development.
- Appointed Perrin Wilson Ph.D. as Senior Vice President of Business Development and Strategy.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$0
Forward guidance
Nuvalent expects its cash, cash equivalents and marketable securities, in combination with the net proceeds from the public offering, to extend the company's operating runway into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2023
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro